

***Fiscal Year 2025 Department of Defense Ovarian Cancer Research Program (OCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Investigator-Initiated Research Award Go to: <ul style="list-style-type: none"> Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT942525OCRPIIRA	Investigators at or above the level of Assistant Professor (or equivalent).	Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. <ul style="list-style-type: none"> Research aimed at extending the lives of advanced state and recurrent patients is encouraged. If cell lines or animals are used, justification for use is required. Preliminary data are required. Clinical trials are not allowed. Partnering Principal Investigator Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator (PI) and receive a separate award. <i>Preproposal submission is required; application submission is by invitation only.</i>	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is: <ul style="list-style-type: none"> \$1,050,000 for total costs (direct + indirect costs) for a single PI \$1,400,000 for total costs (direct + indirect costs) for Partnering PIs The maximum period of performance is 4 years. 	Pre-Application (Preproposal): June 12, 2025 5:00 p.m. Eastern Time (ET) Application: September 11, 2025 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525OCRPOCCTAECI</p>	<p>Investigators must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. A letter attesting to eligibility is required.</p>	<p>Supports the addition of new early-career investigators (ECIs) to the unique, interactive virtual Clinical Trial Academy that provide intensive mentoring, national networking, collaborations and a peer group for junior faculty.</p> <ul style="list-style-type: none"> • Research will support translational research and small-scale, early-phase clinical trials in ovarian cancer. • ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply. • A Designated Mentor with clinical trial experience and an active clinical trial is required. • A Designated Mentor may mentor only one ECI. • The Designated Mentor is not required to be at the same institution as the ECI. • Preliminary data are required. • Clinical trials are allowed. <p><i>Preproposal submission is required; application submission is by invitation only.</i></p>	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,400,000 for total costs (direct + indirect costs). • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): June 12, 2025 5:00 p.m. ET</p> <p>Application: September 11, 2025 11:59 p.m. ET</p>
<p>Pilot Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942525OCRPPA</p>	<p>Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent).</p>	<p>Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.</p> <ul style="list-style-type: none"> • Innovation is an important review criterion. • The goal is to develop preliminary data; thus, preliminary data are not required, but are allowed. • Research aimed at extending the lives of advanced-state and recurrent patients is encouraged. • Clinical trials are not allowed. • Early Detection or Prevention Option: This option supports research that focuses on innovative concepts or theories leading to major advances in the fields of early ovarian cancer detection or ovarian cancer prevention. • Reviewers will be blinded to the identity of the PI, collaborators and their organization(s) <p><i>Preproposal submission is required; application submission is by invitation only.</i></p>	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 for total costs (direct + indirect costs). • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): June 12, 2025 5:00 p.m. ET</p> <p>Application: September 11, 2025 11:59 p.m. ET</p>